Navigation Links
Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Date:7/28/2011

/li>
  • Zaltrap™ (aflibercept) - alliance with Regeneron - in the U.S. in the third quarter and in EU in the fourth quarter of 2011 in second line metastatic colorectal cancer.
  • Lyxumia® (lixisenatide) - licensed from Zealand Pharma - in the EU in the fourth quarter of 2011 for the treatment of type 2 diabetes.
  • Lemtrada (alemtuzumab(11)) is expected to be filed in the U.S. and EU in the first quarter of 2012 for relapsing remitting multiple sclerosis. The product has been granted fast track designation by the FDA.

  • At the end of July, the R&D portfolio comprises 65 NME (New Molecular Entities) projects and vaccines in clinical development of which 17 are in Phase III or have been submitted to the health authorities for approval.

    Evolution of the late stage portfolio: In May, Sanofi announced the Phase III results of GetGoal-L of the GetGoal program assessing the efficacy and safety of Lyxumia® (lixisenatide) - licensed from Zealand Pharma -, a once-daily GLP-1 receptor agonist, as an add-on to basal insulin (in association with or without metformin) in patients with Type 2 diabetes. This study achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with Type 2 diabetes without significantly increasing their risk of hypoglycemia.

    GetGoal-L is one of nine studies in the GetGoal Phase III clinical program, and the second trial to investigate the benefits of lixisenatide 20μg once-daily combined with basal insulin.

    In May, at the American Diabetes Association, results of two other Phase III studies from the GetGoal program were presented:

  • GetGoal-X: This study showed that once-daily Lyxumia® demonstrates non-inferior reduction of blood glucose and less hypoglycemia versus exenatide twice daily in Type 2 diabetes patients.
  • GetGoal-L Asia: This study demonstrated that Lyxu
    '/>"/>

  • SOURCE Sanofi
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. New Senior Executives Appointed at Sanofi:
    2. VR Business Sales, Mergers & Acquisitions Charlotte Completes Sale of Penrod Medical Equipment
    3. Global Medical Devices Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Marketing Spend and Sales Strategies
    4. TPI Ships Macrolide API Samples for International Sales Standard Testing
    5. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
    6. Burlington Medical Supplies Reorganizes Sales and Marketing Operations
    7. HASCO Medical Inc. Names Mike Dumais the Vice President of Sales for Southern Medical and Mobility
    8. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
    9. With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing
    10. TPI Signs Macrolide API International Sales and Marketing Agreement
    11. CellerateRX TV Commercials Begin Airing on Fox News Network via Geraldo at Large and Fox News Sunday Programs, Expanding the Direct-To-Consumer Sales Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... WASHINGTON , Sept. 2, 2014 The ... America,s pharmacy benefit managers (PBMs), today filed a lawsuit ... a sweeping new Iowa law ... drug costs for the state,s employers and consumers.  ... generic drugs by severely restricting the use of Maximum ...
    (Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com ... available in its catalogue: Acute Heart ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute ... Summary GlobalData,s clinical trial report, ... 2014" provides data on the Acute Heart Failure ...
    (Date:9/2/2014)... Spanje, September 2, 2014 ... AF Registry bij het ESC CONGRESS 2014 ... patiënten met risico op beroerte in de ... Gegevens van bijna 12.500 patiënten ingeschreven in ... Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief op ...
    Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10
    ... BioDelivery Sciences International, Inc. (Nasdaq: BDSI ... 1 study assessing the pharmacokinetics of a BEMA ... commercialize a high dose formulation of buprenorphine combined ... of opioid dependence. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ...
    ... -- Golden Meditech Holdings Limited ("Golden ... 801.HK; 910801.TW), which embodies a leading medical devices enterprise, a ... cell cord blood banking operator in China, is pleased to ... With a track record in China for establishing ...
    Cached Medicine Technology:BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 2BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 3BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence 4Golden Meditech Celebrates Grand Opening of Taiwan Representative Office 2Golden Meditech Celebrates Grand Opening of Taiwan Representative Office 3
    (Date:9/2/2014)... San Diego, CA (PRWEB) September 02, 2014 ... guide titled, “Is Group Therapy Right for Me?” The ... joining group therapy or counseling, in addition to common ... in group therapy improve not only from the interventions ... the group and receiving feedback from group members,” says ...
    (Date:9/2/2014)... Atlanta, Ga. (PRWEB) September 02, 2014 ... hosted by, respectively, top-industry professionals Carey Lewis ... each person auditioning, seeking those who have the desire ... chosen for a callback, performers could be invited to ... SHINE convention. , Charlotte, NC – Saturday, Sept. 6, ...
    (Date:9/2/2014)... NV (PRWEB) September 02, 2014 Cloud ... provider of “Cloud Based” Medical Practice Business Operations solutions ... provider of Digital Cyber Security solutions for all industries ... interviewed on the trading floor of the CME in ... Mr. DeLaGarza stated that we are very proud of ...
    (Date:9/2/2014)... 02, 2014 On August 30, 2014, ... titled “Why You Should Wash Your Face .” ... the global population breathes air considered polluted by the ... lodge in the skin’s pores destroying its natural oils. ... free radicals that may cause cell damage, redness, ...
    (Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
    Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3
    ... unpredictable and often fatal, researchers say, , , THURSDAY, July 31 ... aortic dissection could lead to a rapid diagnostic test for ... dissection is a tear in the lining of the aorta, ... rest of the body. About 2,000 people a year in ...
    ... While summer is the time of year people like ... many sinus sufferers from enjoying activities such as barbequing, hanging ... to name a few. , In fact, a new ... sinus sufferers say they miss or cut short social outings ...
    ... thousands of Americans,prepare to attend the upcoming Olympic Games ... -- and how to deal with it -- is,in ... care in foreign lands can be,daunting, but travelers who ... said Angelo Masciantonio, CEO and co-founder of HTH,Worldwide, a ...
    ... announced that the company will report financial results for,the first ... April 24,2009 on Thursday, August 21, 2008 at 8:00 AM ... results on the same day at 9:00 AM EDT., ... To listen to the conference call live by telephone dial ...
    ... consumers. , ... Orlando, FL (Vocus) July 31, 2008 ... vendor in its "Hype Cycle for Healthcare Payers, 2008" report. Connextions, ... attract, retain and manage individual and small group members. ...
    ... Kenneth O.,Klepper, president & chief operating officer, Medco Health ... the BMO Capital Markets 2008 Focus on,Healthcare Conference in ... presentation at the Millennium Broadway Hotel will begin at ... also scheduled to,attend., The presentation may be heard ...
    Cached Medicine News:Health News:Gene Test Could Catch Deadly Heart Problem 2Health News:Gene Test Could Catch Deadly Heart Problem 3Health News:Sinus sufferers miss out on work or social activities due to summer allergies 2Health News:Americans Attending Beijing Olympics Should Plan Ahead for Medical Emergencies 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results 2Health News:Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications 2Health News:Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications 3Health News:Medco to Present at the BMO Capital Markets 2008 Focus on Healthcare Conference 2
    ... HCS INTERACTANT is ... system. Financial applications include ... human resources and comprehensive ... financial applications are designed ...
    ... is intended for the determination of C-Reactive ... on automated clinical chemistry analyzers. The erCRP ... a high sensitive method to ensure a ... entire measurable range (0.15 320mg/L). The ...
    ... Infinity Urea single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Urea reagent provides a long shelf ...
    ... The Infinity Lithium single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Lithium reagent provides a long ...
    Medicine Products: